SCHEMBL30176545

SCHEMBL30176545

CN(C)C(=O)c1cc2cnc(Nc3cnc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 12/20 0.79
CDK1 P06493 8/20 0.63
CDK2 P24941 6/20 0.63
CCND3 P30281 3/20 0.61
CCND1 P24385 3/20 0.60
GAK O14976 1/20 0.60
CCNT1 O60563 1/20 0.60
CCNA2 P20248 1/20 0.60
FECH P22830 1/20 0.60
CDK9 P50750 1/20 0.60
CDK6 Q00534 1/20 0.60
CDK16 Q00536 1/20 0.60
MAP3K1 Q13233 1/20 0.60
CAMK2G Q13555 1/20 0.60
CAMK2D Q13557 1/20 0.60
Q6ZSR9 Q6ZSR9 1/20 0.60
PRKD2 Q9BZL6 1/20 0.60
SIK2 Q9H0K1 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303640 1.00 CDK4 (0.79) CDK4CDK1CDK2CCND3CCND1
SCHEMBL29507579 0.90 CDK4 (0.64) CDK4CDK1CDK2CCND3CCND1
Dimethylamine SCHEMBL28938639 0.89 CDK4 (0.63) CDK4CDK1CDK2CCND3CCND1
SCHEMBL30176576 0.89 CDK4 (0.79) CDK4CDK1CDK2CCND3CCND1
SCHEMBL302194 0.89 CDK4 (0.79) CDK4CDK1CDK2CCND3CCND1
SCHEMBL30176619 0.88 CDK4 (1.00) CDK4CDK1CDK2CCND3CCND1
SCHEMBL303197 0.88 CDK4 (1.00) CDK4CDK1CDK2CCND3CCND1
SCHEMBL30176542 0.88 CDK4 (0.78) CDK4CDK1CDK2CCND3CCND1
SCHEMBL1991337 0.88 CDK4 (0.78) CDK4CDK1CDK2CCND3CCND1
SCHEMBL302216 0.85 CDK4 (0.80) CDK4CDK1CDK2CCND3CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126244-A1 COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) 2023-02-08 EP claimed
EP-4126244-A1 COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) 2023-02-08 EP disclosed